Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia+17 more
wiley +1 more source
One-Pot Parallel Synthesis of Unclosed Cryptands-Searching for Selective Anion Receptors via Static Combinatorial Chemistry Techniques. [PDF]
Niedbała P, Jurczak J.
europepmc +1 more source
Hit-optimization using target-directed dynamic combinatorial chemistry: development of inhibitors of the anti-infective target 1-deoxy-d-xylulose-5-phosphate synthase. [PDF]
Jumde RP+12 more
europepmc +1 more source
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley +1 more source
Papers on combinatorial chemistry or solid-phase synthesis from other journals - March 1999
openalex +1 more source
The dark side of disulfide-based dynamic combinatorial chemistry. [PDF]
Dumartin M+7 more
europepmc +1 more source
Clinical significance of stratifying prostate cancer patients through specific circulating genes
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian+12 more
wiley +1 more source
Papers on combinatorial chemistry or solid-phase synthesis from other journals - September 1998
openalex +1 more source
Using mass cytometry, we analyzed serial blood samples from patients with relapsed epithelial ovarian cancer (EOC) treated with oleclumab–durvalumab combination immunotherapy in the NSGO‐OV‐UMB1/ENGOT‐OV30 trial. Our analysis identified potential predictive, monitoring, and response biomarkers detectable through liquid biopsy. These findings facilitate
Luka Tandaric+11 more
wiley +1 more source